Solid Biosciences (SLDB) News
NASDAQ: SLDBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
6.25-0.19 (-2.95%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SLDB news summary
We found 4 recent headlines mentioning Solid Biosciences (SLDB): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, SLDB is down 2.95% at $6.25. The most recent story, "Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Solid Biosciences headlines
- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceCHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…GlobeNewswire
- Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -GlobeNewswire
- Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…GlobeNewswire
- UBS Initiates Coverage of Solid Biosciences at BuyFintel reports that on October 15, 2026, UBS initiated coverage of Solid Biosciences (NASDAQGS:SLDB) with a Buy recommendation. Prior to this rating action, the stock closed at $5.46 on October 14,…Nasdaq